AR004382A1 - Peptidos, su obtencion y las composiciones farmaceuticas que los contienen. - Google Patents

Peptidos, su obtencion y las composiciones farmaceuticas que los contienen.

Info

Publication number
AR004382A1
AR004382A1 ARP960105673A ARP960105673A AR004382A1 AR 004382 A1 AR004382 A1 AR 004382A1 AR P960105673 A ARP960105673 A AR P960105673A AR P960105673 A ARP960105673 A AR P960105673A AR 004382 A1 AR004382 A1 AR 004382A1
Authority
AR
Argentina
Prior art keywords
obtaining
peptidos
contain
pharmaceutical compositions
new
Prior art date
Application number
ARP960105673A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR004382A1 publication Critical patent/AR004382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nuevos péptidos de la fórmula: R1R2N-CHX-CO-A-B-D-E- (G)s - K en la que R1, R2, A, B, D, E, G, K, X y s, tienen los significados indicados enla memoria descriptiva y la obtención de los mismos, tal y como está descripto en la misma. Lo s nuevoscompuestos tienen un efecto antineoplásico.
ARP960105673A 1995-12-15 1996-12-13 Peptidos, su obtencion y las composiciones farmaceuticas que los contienen. AR004382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57342295A 1995-12-15 1995-12-15

Publications (1)

Publication Number Publication Date
AR004382A1 true AR004382A1 (es) 1998-11-04

Family

ID=24291935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105673A AR004382A1 (es) 1995-12-15 1996-12-13 Peptidos, su obtencion y las composiciones farmaceuticas que los contienen.

Country Status (30)

Country Link
EP (2) EP1593686B1 (es)
JP (1) JP3939354B2 (es)
KR (1) KR100463739B1 (es)
CN (1) CN1127514C (es)
AR (1) AR004382A1 (es)
AT (2) ATE277076T1 (es)
AU (2) AU731458B2 (es)
BG (1) BG64563B1 (es)
BR (1) BR9611987A (es)
CA (1) CA2237721C (es)
CO (1) CO4750840A1 (es)
CZ (1) CZ296908B6 (es)
DE (2) DE69633457T2 (es)
DK (1) DK0866800T3 (es)
ES (1) ES2229287T3 (es)
HR (1) HRP960585A2 (es)
HU (1) HU228275B1 (es)
IL (2) IL124342A (es)
MX (1) MX9803953A (es)
MY (1) MY114327A (es)
NO (1) NO319273B1 (es)
NZ (1) NZ324691A (es)
PL (1) PL186721B1 (es)
PT (1) PT866800E (es)
RU (1) RU2182911C2 (es)
SK (1) SK285286B6 (es)
TR (1) TR199801102T2 (es)
TW (1) TW474946B (es)
WO (1) WO1997022621A2 (es)
ZA (1) ZA9610510B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879276A (en) * 1983-12-19 1989-11-07 Uniroyal Chemical Ltd./Uniroyal Chemical Ltee Method for reducing serum uric acid levels
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
EP0642530B1 (en) * 1992-05-20 1998-08-12 BASF Aktiengesellschaft Derivatives of dolastatin
SG67935A1 (en) * 1992-12-16 1999-10-19 Basf Ag Novel peptides the preparation and use thereof
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof

Also Published As

Publication number Publication date
ATE471944T1 (de) 2010-07-15
EP0866800B1 (en) 2004-09-22
TR199801102T2 (xx) 1998-12-21
NO319273B1 (no) 2005-07-11
DK0866800T3 (da) 2005-01-17
AU2004220772A1 (en) 2004-11-11
AU2004220772B2 (en) 2008-06-12
NO982711D0 (no) 1998-06-12
JP3939354B2 (ja) 2007-07-04
BR9611987A (pt) 1999-02-17
AU731458B2 (en) 2001-03-29
IL124342A0 (en) 1998-12-06
BG102479A (en) 1999-06-30
IL124342A (en) 2005-06-19
SK285286B6 (sk) 2006-10-05
CN1204342A (zh) 1999-01-06
HUP0000172A3 (en) 2000-09-28
EP1593686B1 (en) 2010-06-23
BG64563B1 (bg) 2005-07-29
HU228275B1 (en) 2013-02-28
PT866800E (pt) 2005-01-31
EP0866800A2 (en) 1998-09-30
DE69633457T2 (de) 2005-09-22
AU1192597A (en) 1997-07-14
CA2237721C (en) 2008-01-29
NO982711L (no) 1998-06-12
ZA9610510B (en) 1998-06-15
JP2000502092A (ja) 2000-02-22
MX9803953A (es) 1998-09-30
TW474946B (en) 2002-02-01
MY114327A (en) 2002-09-30
KR20000064400A (ko) 2000-11-06
KR100463739B1 (ko) 2005-02-28
DE69638206D1 (de) 2010-08-05
CN1127514C (zh) 2003-11-12
HUP0000172A2 (en) 2000-07-28
CZ184698A3 (cs) 1998-09-16
CZ296908B6 (cs) 2006-07-12
ATE277076T1 (de) 2004-10-15
WO1997022621A2 (en) 1997-06-26
ES2229287T3 (es) 2005-04-16
EP1593686A1 (en) 2005-11-09
PL186721B1 (pl) 2004-02-27
IL166853A (en) 2013-03-24
RU2182911C2 (ru) 2002-05-27
HRP960585A2 (en) 1998-02-28
SK76798A3 (en) 1999-02-11
WO1997022621A3 (en) 1998-02-26
PL327175A1 (en) 1998-11-23
DE69633457D1 (de) 2004-10-28
CA2237721A1 (en) 1997-06-26
CO4750840A1 (es) 1999-03-31
NZ324691A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
UY28348A1 (es) Compuestos novedosos
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
AR002277A1 (es) Compuestos utiles como inhibidores de la trombina, composiciones farmaceuticas que los contienen y sustancias peptidicas y peptidomimeticasinhibidoras de la serinproteasa.
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
IS2303B (is) Glýkópeptíð fosfónatafleiður
ES2151921T3 (es) Analogo de dolastatina.
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
ATE231872T1 (de) Thiazolopyrimidinderivate
AR030185A1 (es) Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas
ES2193508T3 (es) Ftalizinonas.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
PA8466101A1 (es) Agentes terapeuticos
AR028947A1 (es) Compuestos novedosos
AR004382A1 (es) Peptidos, su obtencion y las composiciones farmaceuticas que los contienen.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FG Grant, registration
FG Grant, registration